Navigation Links
Delcath Adds Dr. Pamela R. Contag to Its Board of Directors
Date:12/17/2008

NEW YORK, Dec. 17/PRNewswire-FirstCall/ -- Delcath Systems, Inc. (Nasdaq: DCTH) today announced the appointment of Pamela R. Contag, Ph.D., to Delcath's Board of Directors. Dr. Contag is a proven corporate executive with extensive experience working with international and domestic investors.

(LOGO: http://www.newscom.com/cgi-bin/prnh/20081118/NY46990LOGO )

Dr. Contag founded Cobalt Technologies, Inc. in 2006 and served as CEO. Prior to starting Cobalt, she founded Xenogen Corporation, a biotechnology company specializing in technology and services for preclinical drug development and testing. She served as President and Director of Xenogen from 1995 to 2006. Xenogen, which became a public company in 2004, was acquired by Caliper Life Sciences in 2006. Xenogen Corporation was listed as one of the "Top 25 Young Businesses" by Fortune Small Business and twice received the "R&D 100 Award." Dr. Contag was also recognized as one of the "Top 25 Women in Small Business" by Fortune magazine.

Dr. Contag received her Ph.D. in Microbiology from the University of Minnesota Medical School and completed her postdoctoral training at Stanford University School of Medicine. Dr. Contag is a consulting Professor at the Stanford School of Medicine and is widely published in the field of non-invasive molecular and cellular imaging.

Richard L. Taney, President and Chief Executive Officer of Delcath, welcomed Dr. Contag to the Board, stating, "Delcath continues to add strategic insight and expertise to our Board of Directors as we focus on the completion of our trial and approval of the Delcath PHP System. Dr. Contag's biotech, pharmaceutical and testing experience will be particularly relevant as we prepare for meetings with the FDA regarding regulatory approvals and ultimately, commercialization. Her extensive industry relationships will provide opportunities to expand the recognition and value of the Delcath technology. The recent clinical milestones, and addition of key management and Board members over the past six months, have positioned our Company well, as enrollment continues to accelerate and we move towards completion of our Phase III trial."

About Delcath Systems, Inc.

Delcath Systems, Inc. is a medical technology company specializing in cancer treatment. The Company is testing a proprietary, patented drug delivery system for the treatment of liver cancers. Delcath's novel drug delivery platform is testing the delivery of ultra-high doses of anti-cancer drugs to the liver while preventing these high doses of drug from entering the patient's bloodstream. The Company is currently enrolling patients in Phase III and Phase II clinical studies for the treatment of liver cancers using high doses of melphalan. The Company's intellectual property portfolio consists of twenty-eight patents on a worldwide basis including the U.S., Europe, Asia and Canada. For more information, please visit the Company's website at http://www.delcath.com/

The Private Securities Litigation Reform Act of 1995 provides a safe harbor for forward-looking statements made by the Company or on its behalf. This news release contains forward-looking statements, which are subject to certain risks and uncertainties that can cause actual results to differ materially from those described. Factors that may cause such differences include, but are not limited to, uncertainties relating to our ability to successfully complete Phase III clinical trials and secure regulatory approval of our current or future drug-delivery system and uncertainties regarding our ability to obtain financial and other resources for any research, development and commercialization activities. These factors, and others, are discussed from time to time in our filings with the Securities and Exchange Commission. You should not place undue reliance on these forward-looking statements, which speak only as of the date they are made. We undertake no obligation to publicly update or revise these forward-looking statements to reflect events or circumstances after the date they are made.


'/>"/>
SOURCE Delcath Systems, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Delcath Expands Phase III Trial for Metastatic Melanoma to Include St. Lukes Cancer Center
2. Delcath Updates Phase III Patient Enrollment as Pivotal Trial Accelerates, Durable Tumor Responses In Phase II Study Also Cited
3. Delcath Expands Phase III Trial for Metastatic Melanoma to Include University of Maryland Medical Center
4. Aegerion Pharmaceuticals, Inc. adds Peter Garrambone to Board of Directors, Secures Additional Capital for Clinical Trials
5. Velcura Therapeutics, Inc. Adds William Brinkerhoff to its Board of Directors
6. Silence Therapeutics Announces Board Changes
7. ASPIRE Independent Review Board Announces 10 Ways to Protect Participants Rights in Clinical Drug Trials and Optimize Results From Research
8. UBC Forms European Advisory Board to Enhance Data Quality of CNS Trials
9. Independent Data Safety Monitoring Board Recommends Continuation of Sangarts Pivotal Phase III Trials of Hemospan(R) Following Second Interim Review
10. William R. Ringo Joins Hyperion Therapeutics, Inc. Board of Directors as Chairman
11. Berkery Noyes Represented The Thomson Corporation in the Sale of CenterWatch and New England Institutional Review Board to Jobson Medical Information
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/2/2017)... , Aug. 2, 2017 ... Who,s Who as a Pinnacle Lifetime Professional in ... Key Account Manager at Turing Pharmaceuticals, AG. Her ... troubleshooting and relationship building.                ... more than 25 years of experience as a ...
(Date:7/31/2017)... Pharmacy, Inc. (NYSE: DPLO), has been named one of the ... Crain,s Detroit Business . The annual Crain,s Fast ... growth. This year,s edition measures growth from 2013 to 2016. ... list, visit crainsdetroit.com/awards/fast_50/2017 .  "Being named ... Phil Hagerman , CEO and chairman of Diplomat. "We,ve made ...
(Date:7/27/2017)... 2017  Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH) ... 30, 2017.  The Company reported second quarter net sales ... prior year period, and an increase of 2.1% on ... of contribution from the LDR Holding Corporation acquisition, second ... of 2016, or 0.3% on a constant currency basis. ...
Breaking Medicine Technology:
(Date:8/22/2017)... ... ... past six years, Lightning Labels has sent out a call for users of its custom ... creativity of their designs. Submissions this year were open from May 18 to July 1 ... winners of the sixth annual Photo Contest, along with the prizes they've received:, ...
(Date:8/22/2017)... ... August 22, 2017 , ... “Wilderness Voices”: a collection ... travel. “Wilderness Voices” is the creation of published author, Martha McKown, an ordained ... was inspired as a very young child when her older sisters studied High School ...
(Date:8/22/2017)... ... , ... TopConsumerReviews.com recently gave a best-in-class 5-star rating to Energy NADH, a ... of modern life continually makes more demands on time and energy, people are finding ... people in vicious high/low cycles and can also cause long term health issues. More ...
(Date:8/21/2017)... ... August 22, 2017 , ... ... I. Stevens as a 2017-2018 inductee into its VIP Woman of the ... NAPW is the nation’s leading networking organization exclusively for professional women, boasting more ...
(Date:8/21/2017)... ... 2017 , ... Marathon running has surged in popularity in ... running increases exposure to ultraviolet radiation, a carcinogen that promotes skin cancer. Studies ... half may be adequately protecting themselves with proper clothing and sunscreen. , ...
Breaking Medicine News(10 mins):